HeyJaredAlessandra Luciano
Macro signals, factor investing, and the assumptions the market forgets to question.
- Indexed issues, last 90 days
- 7
- Latest publication
- Sep 22, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 7, 2026
Latest issues
How to Read a Rare-Earth Rocket (opens the original)
Read excerpt
This is not a piece about whether to buy a stock. It is a piece about how to read one — specifically, the kind of pre-revenue critical-minerals developer that goes vertical when geopolitics puts its commodity on the front page. These rallies are becoming a fixture of the market, and they share an anatomy. Learn the anatomy and you can tell, quickly, how much of any given move is a real change in value and how much is narrative borrowing against a future that may never arrive.The trade that keeps
Zillow: A Cyclical Stock Wrapped Around a Non-Cyclical Business (opens the original)
Read excerpt
Here is the mispricing in one sentence: Zillow’s share price is cyclical on interest rates, but its business no longer is. The stock trades as a leveraged bet on the US mortgage market — rates up, stock down — while underneath it the company has quietly rebuilt itself into something that grew revenue through the sharpest rate-hiking cycle in forty years… Read more
Reverse DCF: What the Market Is Actually Pricing Into Nvidia (opens the original)
Read excerpt
Every valuation debate about a great company eventually collapses into the same unwinnable argument: your growth assumptions against mine. The reverse DCF sidesteps it entirely. Instead of forecasting the future to produce a value, it takes the market’s value as given and solves for the future implied in it. The output is not a price target. It is a hyp… Read more
DPI Is the New IRR (opens the original)
Read excerpt
TVPI is an opinion. DPI is a wire transfer. For a decade of rising markets the distinction was academic — paper value and realized value climbed together, and the industry’s favorite number, IRR, flattered both. Then exits stopped. Four years into the deepest liquidity drought in modern private equity, limited partners have quietly demoted every metric … Read more
From $9.9 Billion to Zero: The Anatomy of a Failed LBO (opens the original)
Read excerpt
When a leveraged buyout fails, the autopsy usually looks for an operational cause: a bad roll-up, a missed technology shift, fraud. Envision Healthcare offers something rarer and more instructive — an LBO that failed while its diagnosis at entry was largely correct. The business was what the model said it was. What the model could not hold was seven turns of leverage against a revenue pool that Congress, a single payor, and a pandemic could each reprice at will.The deal everyone wantedIn June 20
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.